Guardant Health Showcases Innovations in Precision Oncology at SABCS 2024

Guardant Health Advances Precision Oncology at SABCS 2024

Guardant Health, Inc., a leading name in precision oncology based in Palo Alto, California, prepares to unveil its latest innovations at the San Antonio Breast Cancer Symposium (SABCS) 2024, scheduled for December 10-13, 2024. The company plans to present eight posters that reflect significant progress in the realm of circulating tumor DNA (ctDNA) analysis, particularly through the Guardant Reveal test, an epigenomic assay designed to assess ctDNA dynamics during neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer. These findings are poised to provide critical insights into tumor burden and therapy sensitivity, while also identifying resistance mutations that could impact patient outcomes.

Dr. Craig Eagle, Chief Medical Officer at Guardant Health, underscores the company's commitment to utilizing precision oncology tools to enhance treatment selection and monitor cancer recurrence effectively. The presentations at the symposium will span a variety of topics, including real-world outcomes associated with elacestrant treatment in advanced breast cancer patients, as well as genomic responses in patients undergoing CDK4/6 inhibitor therapy. These studies aim to illustrate the relevance of ctDNA analysis in predicting patient outcomes, thereby fostering more personalized treatment strategies and improved patient management.

In addition to the Guardant Reveal test, the presentations will spotlight other significant products, including GuardantINFORM™, Guardant Infinity™, and Guardant360® CDx. A pivotal aspect of the symposium is the presentation of data from 2,000 breast cancer patients, focusing on the real-world impact of minimal residual disease testing. This extensive research emphasizes Guardant Health's collaboration with researchers and cancer care teams, further solidifying its role in advancing precision medicine and optimizing therapeutic approaches for individuals affected by breast cancer.

Alongside its poster presentations, Guardant Health aims to foster dialogue on the integration of genomic data in clinical practice. The company's ongoing collaboration with healthcare professionals is crucial in translating research findings into actionable insights that can enhance patient care. As Guardant Health continues to pioneer advancements in precision oncology, its contributions to the SABCS 2024 symposium highlight the potential of ctDNA analysis to transform treatment paradigms and improve outcomes for breast cancer patients.